Solid lipid nanoparticles containing nimesulide: Preparation, characterization and cytotoxicity studies

Current Nanoscience

Volumn 5, Issue 1, 2009, Pages 39-44

  Bondi, Maria Luisa ^a   Azzolina, Antonina ^b   Craparo, Emanuela Fabiola ^c   Capuano, Giulia ^c   Lampiasi, Nadia ^b   Giammona, Gaetano ^c   Cervello, Melchiorre ^b  

^a CNR   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

Author keywords

Drug release; Human colon adenocarcinoma cells; Nimesulide; Solid lipid nanoparticles; Solid tumours

Indexed keywords

ANTICANCER COMPOUNDS; ANTIPROLIFERATIVE EFFECT; ANTITUMOUR ACTIVITY; BLOOD CIRCULATION; CANCER THERAPY; CELL LINES; COLLOIDAL SIZE; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; ENHANCED PERMEABILITY AND RETENTION EFFECTS; HUMAN COLON ADENOCARCINOMA CELLS; IN-VITRO; INTRAVENOUS ADMINISTRATION; LOADING CAPACITIES; NEGATIVE ZETA POTENTIALS; NIMESULIDE; NON-STEROIDAL ANTI-INFLAMMATORY DRUGS; SOLID LIPID NANOPARTICLES; TUMOURS;

CARDIOVASCULAR SYSTEM; CELL CULTURE; DRUG DELIVERY; NANOPARTICLES; ONCOLOGY; SOLUBILITY; TERNARY SYSTEMS; ZETA POTENTIAL;

TUMORS;

NIMESULIDE; SOLID LIPID NANOPARTICLE;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CELL FREE SYSTEM; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVIEW; ZETA POTENTIAL;

EID: 65949107820     PISSN: 15734137     EISSN: None     Source Type: Journal    
DOI: 10.2174/157341309787314575     Document Type: Review

References (36)

1. Wong, H.L.; Bendayan, R.; Rauth, A.M.; Li, Y.; Wu, X.Y. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Deliv. Rev., 2007, 59, 491-504.
2. Allen, T.M.; Cullis, P.R. Drug delivery systems: Entering the mainstream. Science, 2004, 303, 1818-1822.
3. Jaspreet, K.V.; Maram, K.R.; Vinod, D.L. Nanosystems in drug targeting: opportunities and challenges. Curr. Nanosci., 2005, 1, 47-64.
4. Matsumura, Y.; Maeda, H. A New concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of protein and the antitumor agent smancs. Cancer Res., 1986, 46, 6387-6392.
5. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the epr effect in macromolecular therapeutics: A review. J. Control. Release, 2000, 65, 271-284.
6. Brigger, I.; Dubernet, C.; Couvreur, P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev., 2002, 54, 631-651.
7. Serpe, L.; Catalano, M.G.; Cavalli, R.; Ugazio, E.; Bosco, O.; Canapaio, R.; Muntoni, E.; Frairia, R.; Gasco, M.R.; Eandi, M.; Zara. G.P. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on ht-29 colorectal cancer cell line. Eur. J. Pharm. Biopharm., 2004, 58, 673-680.
8. Miura, H.; Onischi, H.; Sasatsu, M.; Machida, Y. Antitumor characteristics of methoxypolyethylene glycol-poly(d,l-lactic acid) nanoparticles containing camptothecin. J. Control. Release, 2004, 97, 101-113.
9. Muller, R.H.; Mader, K.; Gohla, S. Solid lipid nanoparticles (sln) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm., 2000, 50, 161-177.
10. Yang, S.; Lu, Y.; Cai, Y.; Zhu, J.; Liang, B.; Yang, C. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Control. Release, 1999, 59, 299-307.
11. Fundarò, A.; Cavalli, R.; Bargoni, A.; Vighetto, D.; Zara, G. P.; Gasco, M. R. Non-stealth and stealth solid lipid nanoparticles (sln) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol. Res., 2000, 42, 337-343.
12. Pinto, J.F.; Muller, R.H. Pellets as carriers of solid lipid nanoparticles (sln) for oral administration of drugs. Die Pharmazie, 1999, 54, 506-509.
13. Ricchi, P.; Zarrilli, R.; Di Palma, A.; Acquaviva, A.M. Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy. Br. J. Cancer, 2003, 88, 803-807.
14. Shaik, M.S.; Chatterjee, A.; Singh M. Effect of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of lung tumors and their expression of cyclooxygenase-2 and peroxisome proliferator- activated receptor-γ. Clin. Cancer Res., 2004, 10, 1521-1529.
15. Foderà, D.; D'Alessandro, N.; Cusimano, A.; Poma, P.; Notarbartolo, M.; Lampiasi, N.; Montalto, G.; Cervello M. Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by cox-2 inhibitors. Ann. N. Y. Acad. Sci., 2004, 1028, 1-10.
16. Eberhart, C.E.; Coffey, R.J.; Radhika, A.; Giardiello, F.M.; Ferrenbach, S.; DuBois, R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 1994, 107, 1183-1188.
17. Parrete, M.L.; Harris, R.E.; Joarde, F.S.; Ross, M.S.; Clausen, K.P.; Robertson, F.M. Cyclooxygenase-2 expression in human breast cancer. Int. J. Oncol., 1997, 10, 503-507.
18. Gupta, S.; Srivastasava, M.; Ahmad, N.; Bostwick, D.G.; Mukhtar, H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate, 2000, 42, 73-78.
19. Zimmermann, K.C.; Sarbia, M.; Weber, A.A.; Borchard, F.; Gabbert, H.E.; Schror, K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res., 1999, 59, 198-204.
20. Tucker, O.N.; Dannenberg, A.J.; Yang, E.K.; Zhang, F.; Teng, L.; Daly, J.M.; Soslow, R.A.; Woerner, B.M.; Koki, A.T.; Fahey, T.J. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res., 1999, 59, 987-990.
21. Shiota, G.; Okubo, M.; Noumi, T.; Noguchi, N.; Oyama. K.; Takano, Y.; Yashima, K.; Kishimoto, Y.; Kawasaki, H. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology, 1999, 46, 407-412.
22. Chan, G.; Boyle, J.O.; Yang, E.K.; Zhang, F.; Sacks, P.G.; Shah, J.P.; Edelstein, D.; Soslow, R.A.; Koki, A.T.; Woerner, B.M.; Masferrer, J.L.; Dannenberg, A.J. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res., 1999, 59, 991-994.
23. Huang, M.; Stolina, M.; Sharma, S.; Mao, J.T.; Zhu L.; Miller, P.W.; Wolliman, J.; Herschman, H.; Dubinett, S.M. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res., 1998, 58, 1208-1216.
24. Ishizaki, T.; Katsumata, K.; Tsuchida, A.; Wada, T.; Mori, Y.; Hisada, M.; Kawakita, H.; Aoki, T. Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of mmp-9 activity. Int. J. Mol. Med., 2006, 17, 357-362.
25. Nakatsugi, S.; Fukutake, M.; Takahashi, M.; Fukuda, K.; Isoi, T.; Taniguchi, Y.; Sugimura, T.; Wakabayashi, K. Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase-2 inhibitor, in min mice. Jpn. J. Cancer Res., 1997, 88, 1117-1120.
26. Nakatsugi, S.; Ohta, T.; Kawamori, T., Mutoh, M.; Tanigawa, T.; Watanabe, K.; Sugie, S.; Sugimura, T.; Wakabayashi. K. Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (phip)-induced mammary gland carcinogenesis in rats. Jpn. J. Cancer Res., 2000, 9, 886-892.
27. Haynes, A.H.; Shaik, M.S.; Chatterjee, A.; Singh, M. Evaluation of an aerosolized selective cox-2 inhibitor as a potentiator of doxorubicin in a non-small-cell lung cancer cell line. Pharm. Res., 2003, 20, 1485-1495.
28. Fukutake, M.; Nakatsugi, S.; Isoi, T.; Takahashi, M.; Ohta, T.; Mamiya, S.; Taniguchi, Y.; Sato, H.; Fukuda, K.; Sugimura, T.; Wakabayashi, K. Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice. Carcinogenesis, 1998, 19, 1939-1942.
29. Okajima, E.; Denda, A.; Ozono, S.; Takahama, M.; Akai, H.; Sasaki, Y.; Kitayama, W.; Wakabayashi, K.; Konishi, Y. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by n-butyl-n-(4-hydroxybutyl)nitrosamine. Cancer Res., 1998, 58, 3028-3031.
30. Shiotani, H.; Denda, A.; Yamamoto, K.; Kitayama, W.; Endoh, T.; Sasaki, Y.; Tsutsumi, M.; Sugimura, M.; Konishi, Y. Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. Cancer Res., 2001, 61, 1451-1456.
31. Denda. A.; Kitayama, W.; Murata, A.; Kishida, H.; Sasaki, Y.; Kusuoka, O.; Tsujiuchi, T.; Tsutsumi, M.; Nakae, D.; Takagi, H.; Konishi, Y. Increased expression of cyclooxygenase-2 protein during rat hepatocarcinogenesis caused by a choline-deficient, l-amino acid-defined diet and chemopreventive efficacy of a specific inhibitor, nimesulide. Carcinogenesis, 2002, 23, 245-256.
32. Zur Mulhen, A.; Schwarz, C.; Mehnert, W. Solid lipid nanoparticles (sln) for controlled drug delivery-drug release and release mechanism. Eur. J. Pharm. Biopharm., 1998, 45, 149-155.
33. Lim, S.J.; Kim C.K. Formulation parameters determining the physicochemical characteristics of solid lipid nanoparticles loaded with all-trans retinoic acid. Int. J. Pharm., 2002, 243, 135-146.
34. Ugazio E.; Cavalli R.; Gasco M.R. Incorporation of cyclosporin a in solid lipid nanoparticles (sln). Int. J. Pharm., 2002, 241, 341-344.
35. Bondì M.L.; Craparo E.F.; Giammona G.; Cervello M.; Azzolina A.; Diana P.; Martorana A.; Cirrincione G. Nanostructured lipid carriers-containing anticancer compounds: preparation, characterization, and cytotoxicity studies. Drug Deliv., 2007, 14, 61-67.
36. Piel, G.; Pirotte, B.; Delneuveille, I. Study of the influence of both cyclodextrins and l-lysine on the aqueous solubility of nimesulide; isolation and characterization of nimesulide-l-lysine-cyclodextrin complexes. J. Pharm. Sci., 1997, 86, 475-480.